Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,272 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07159815 | REACT - Resistance Exercise After Cancer Treatment(REACT) | active not recruiting | N/A | 160 | Inland Norway University of Applied SciencesOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03106324 | A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant | completed | — | 911 | CelgeneINDUSTRY | 12 | May 28, 2026 |
| clinicaltrials |
| NCT05144841 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | completed | Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 28, 2026 | clinicaltrials |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
| NCT05064059 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | completed | Phase 3 | 441 | Merck Sharp & Dohme LLCINDUSTRY | 21 | May 26, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT03151629 | International Registry for Men With Advanced Prostate Cancer (IRONMAN)(IRONMAN) | recruiting | — | 5,000 | Prostate Cancer Clinical Trials ConsortiumOTHER | 15 | May 22, 2026 | clinicaltrials |
| NCT03260894 | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | completed | Phase 3 | 129 | Incyte CorporationINDUSTRY | 20 | May 22, 2026 | clinicaltrials |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)(EPCORE DLBCL-1) | active not recruiting | Phase 3 | 483 | GenmabINDUSTRY | 24 | May 22, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT07602010 | Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging | recruiting | — | 150 | Oslo University HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06504147 | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | recruiting | Phase 2 | 114 | Oncoinvent Solutions ASINDUSTRY | 6 | May 20, 2026 | clinicaltrials |
| NCT04380636 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | active not recruiting | Phase 3 | 870 | Merck Sharp & Dohme LLCINDUSTRY | 26 | May 15, 2026 | clinicaltrials |
| NCT07580300 | Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.(PRORADNOR-RCT) | recruiting | Phase 3 | 400 | Oslo University HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03776591 | Open D3 Right Hemicolectomy Compared to Laparoscopic CME for Right Sided Colon Cancer(D3/CME) | active not recruiting | N/A | 128 | Haraldsplass Deaconess HospitalOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | active not recruiting | Phase 3 | 755 | Merck Sharp & Dohme LLCINDUSTRY | 23 | May 14, 2026 | clinicaltrials |
| NCT05566795 | DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | active not recruiting | Phase 3 | 418 | Day One Biopharmaceuticals, Inc.INDUSTRY | 30 | May 14, 2026 | clinicaltrials |
| NCT03017326 | Paediatric Hepatic International Tumour Trial(PHITT) | active not recruiting | Phase 3 | 450 | University of BirminghamOTHER | 14 | May 13, 2026 | clinicaltrials |
| NCT03775980 | CIRSE Emprint Microwave Ablation Registry(CIEMAR) | completed | — | 500 | Cardiovascular and Interventional Radiological Society of EuropeOTHER | 13 | May 13, 2026 | clinicaltrials |
| NCT04550897 | A Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients(BM7PE) | terminated | Phase 1 / Phase 2 | 14 | Oslo University HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05634889 | The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.(T-REX) | recruiting | N/A | 1,350 | Region SkaneOTHER | 3 | May 11, 2026 | clinicaltrials |
| NCT06724198 | Bowel Dysfunction After Low Rectal Resection. An Pilot Study Using Psyllium Husk In Rectal Cancer Patients. | completed | N/A | 24 | Sykehuset TelemarkOTHER_GOV | 1 | May 11, 2026 | clinicaltrials |
| NCT05368090 | Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism | recruiting | N/A | 60 | Haukeland University HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)(INTerpath-007) | terminated | Phase 2 / Phase 3 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 20 | May 8, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma(LBL 2018) | recruiting | Phase 3 | 683 | University Hospital MuensterOTHER | 21 | May 6, 2026 | clinicaltrials |
| NCT04126200 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)(DREAMM 5) | active not recruiting | Phase 1 / Phase 2 | 208 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT07084896 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 106 | GlaxoSmithKlineINDUSTRY | 13 | May 6, 2026 | clinicaltrials |
| NCT05173987 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | active not recruiting | Phase 3 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 27 | May 5, 2026 | clinicaltrials |
| NCT05429268 | Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)(firmMIND) | active not recruiting | Phase 3 | 82 | Incyte CorporationINDUSTRY | 14 | May 5, 2026 | clinicaltrials |
| NCT07530952 | Green VR for Depression(VR&depression) | completed | N/A | 45 | Sykehuset Innlandet HFOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06362707 | Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)(FEAD) | recruiting | Phase 2 | 200 | Helse Stavanger HFOTHER_GOV | 1 | May 4, 2026 | clinicaltrials |
| NCT01558921 | Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial(RAPIDO) | active not recruiting | Phase 3 | 920 | University Medical Center GroningenOTHER | 7 | May 1, 2026 | clinicaltrials |
| NCT03711032 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) | active not recruiting | Phase 3 | 1,397 | Merck Sharp & Dohme LLCINDUSTRY | 30 | May 1, 2026 | clinicaltrials |
| NCT05190172 | PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas(PRO-GLIO) | recruiting | N/A | 225 | Oslo University HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01762813 | Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer(ACROBATICC) | recruiting | — | 1,200 | Helse Stavanger HFOTHER_GOV | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03206671 | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents(B-NHL 2013) | active not recruiting | Phase 3 | 650 | University Hospital MuensterOTHER | 8 | Apr 30, 2026 | clinicaltrials |
| NCT04608318 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)(CLL17) | active not recruiting | Phase 3 | 897 | German CLL Study GroupOTHER | 13 | Apr 30, 2026 | clinicaltrials |
| NCT06752850 | A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis | active not recruiting | Phase 4 | 37 | Swedish Orphan BiovitrumINDUSTRY | 4 | Apr 30, 2026 | clinicaltrials |
| NCT07171554 | Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer(DSEE-CRC) | recruiting | N/A | 75 | Oncosyne ASINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03631173 | Monitoring of patIents With Microdialysis Following Pancreaticoduodenectomy(MINIMUM) | active not recruiting | N/A | 201 | Oslo University HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03580655 | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | completed | Phase 2 | 107 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 24, 2026 | clinicaltrials |
| NCT05732623 | Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer(DEMETRA) | recruiting | — | 2,300 | San Raffaele UniversityOTHER | 6 | Apr 24, 2026 | clinicaltrials |
| NCT07545486 | Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment(ATOM-1st) | not yet recruiting | — | 1,235 | ChirecOTHER | 5 | Apr 22, 2026 | clinicaltrials |
| NCT01682083 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).(COMBI-AD) | completed | Phase 3 | 870 | Novartis PharmaceuticalsINDUSTRY | 25 | Apr 21, 2026 | clinicaltrials |
| NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix(BEATcc) | completed | Phase 3 | 410 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 8 | Apr 21, 2026 | clinicaltrials |
| NCT03732768 | Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis | completed | Phase 1 | 21 | Oncoinvent Solutions ASINDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials